Daily Cosmetic Research Analysis
Analyzed 22 papers and selected 3 impactful papers.
Summary
Three clinically relevant studies span surgical innovation and cosmetic dermatology. A randomized non-inferiority trial shows vNOTES matches laparoscopy for ovarian cystectomy while reducing pain and improving cosmetic considerations; an RCT finds 0.6% selenium disulfide shampoo equals 2% ketoconazole for seborrheic dermatitis with superior hair cosmesis; and a PRISMA-ScR scoping review maps early clinical evidence and safety signals for exosome-based dermatologic therapies.
Research Themes
- Minimally invasive gynecologic surgery with improved cosmetic outcomes
- Evidence-based comparative effectiveness in cosmetic dermatology
- Emerging biologic therapies (exosomes) and safety/regulatory landscape
Selected Articles
1. Vaginal natural orifice transluminal endoscopic surgery versus laparoscopy for ovarian cystectomy: a prospective, open-label, randomized, non-inferiority pilot trial.
In a stratified, randomized non-inferiority pilot trial (n=64), vNOTES achieved comparable procedural success to laparoscopy for ovarian cystectomy and significantly reduced postoperative pain (median VAS difference −1). The authors note advantages in cosmetic considerations owing to the transvaginal approach.
Impact: Provides randomized evidence supporting vNOTES as a cosmetically favorable, less painful alternative to laparoscopy for selected patients.
Clinical Implications: vNOTES can be offered to appropriate patients seeking minimal scarring and lower postoperative pain without compromising procedural success; preoperative counseling should address candidacy and surgeon experience.
Key Findings
- vNOTES was non-inferior to laparoscopy for procedural success (lower one-sided 95% CI for stratified risk difference −12.7% > −15% margin).
- Postoperative pain scores were significantly lower with vNOTES (median difference −1; 95% CI −1 to −1; p<0.001).
- Randomization was stratified by tumor size and analyzed by intention-to-treat.
Methodological Strengths
- Prospective randomized non-inferiority design with stratified randomization and ITT analysis
- Clinically relevant outcomes including procedural success and pain scores
Limitations
- Open-label design may introduce performance and detection bias
- Pilot sample size (n=64) with limited power for rare complications and longer-term outcomes
Future Directions: Larger, multicenter, blinded-assessment trials should confirm non-inferiority, quantify cosmetic outcomes, sexual function, and long-term complications, and refine selection criteria.
PURPOSE: Vaginal natural orifice transluminal endoscopic surgery (vNOTES) is an innovative minimally invasive procedure. The study aimed to evaluate whether vNOTES achieves non-inferior results compared to conventional laparoscopy in patients undergoing ovarian cystectomy. METHODS: Participants with benign ovarian tumors were randomly assigned (1:1) to undergo laparoscopy or vNOTES. Randomization was stratified based on the size of the ovarian tumor. Patients and surgeons were aware of the allocated procedures. The primary outcome was the proportion of patients successfully treated by the allocated procedure (non-inferiority hypothesis, margin of 15%). The secondary outcomes included operative time, estimated blood loss, time for specimen retrieval, postoperative pain score, use of analgesics, time to first flatus, and perioperative complications. RESULTS: Sixty-four patients were randomly assigned to laparoscopy (n = 32) and vNOTES (n = 32) and were included in the intention-to-treat analysis. The success rates were 100% and 96.9%, respectively. Non-inferiority of vNOTES was demonstrated, as the lower limit of the one-sided 95% confidence interval for the stratified risk difference was -12.7%, which lies above the pre-specified non-inferiority margin of -15%. The vNOTES group exhibited lower pain scores, with a median difference of -1 (95% CI -1 - -1, p < 0.001). CONCLUSION: vNOTES demonstrates non-inferiority to laparoscopy for ovarian cystectomy in selected patients, with notable advantages in cosmetic outcomes and reduced postoperative pain. CLINICAL TRIAL IDENTIFICATION NUMBER: ChiCTR2300070890.
2. Beyond Efficacy: 0.6% Selenium Disulfide Shampoo Matches 2% Ketoconazole for Seborrheic Dermatitis with Superior Cosmesis.
In a 6-week, randomized double-blind trial (n=87), 0.6% selenium disulfide shampoo matched 2% ketoconazole for clinical efficacy and pruritus reduction, with excellent tolerability for both. Participants across curl types significantly preferred selenium disulfide for hair feel/appearance.
Impact: Demonstrates equivalence in efficacy with superior cosmetic performance, a factor likely to improve adherence and patient satisfaction in seborrheic dermatitis management.
Clinical Implications: Either shampoo can be selected for moderate–severe seborrheic dermatitis; given similar efficacy, hair feel/appearance and patient preference may guide choice to enhance adherence.
Key Findings
- Total Scale Score reductions: ketoconazole −69.5% vs selenium disulfide −77.9% (both P<0.001), with no between-group efficacy difference.
- Symptomatic Scale of Seborrheic Dermatitis reductions: ketoconazole −68.0% vs selenium disulfide −74.5% (both P<0.001).
- Cosmetic attributes favored selenium disulfide across diverse curl types (softer, glossier, more natural hair; P<0.001); tolerability was excellent in both arms.
Methodological Strengths
- Randomized double-blind design with blinded dermatologic global assessment
- Use of validated clinical scales (TSS, SSSD) and inclusion of patient-reported cosmetic endpoints
Limitations
- Single-center study with 6-week duration limits generalizability and long-term efficacy/safety assessment
- Not powered to assess relapse rates or rare adverse events
Future Directions: Longer, multicenter trials should evaluate sustained control, relapse prevention, microbiome effects, and adherence outcomes driven by cosmetic preferences.
BACKGROUND: Although most dandruff shampoos are effective, many leave hair dry and unmanageable, potentially impacting patient compliance and treatment outcomes. OBJECTIVE: This study compared the efficacy, tolerability, and cosmetic benefits of 0.6% micronized selenium disulfide shampoo (SeS2) to 2% ketoconazole shampoo. METHODS: Eighty-seven male and female subjects with moderate to severe dandruff participated in a single-center, 6-week, randomized, double-blind study comparing the benefits and attributes of the shampoos. RESULTS: After 6 weeks of use, Total Scale Score (TSS) decreased by 69.5% in the ketoconazole group, and 77.9% in the SeS2 group, and Symptomatic Scale of Seborrheic Dermatitis (SSSD) decreased by 68.0% in the ketoconazole group and 74.5% in the SeS2 group (all P<0.001). Pruritus severity score decreased by 76.2% and 75.9% in the ketoconazole and SeS2 groups, respectively, and global efficacy and satisfaction, as assessed by blinded dermatologic evaluation, showed significant improvement with both products (all P<0.001). There was no significant difference between the two groups for these outcomes at any time point. Tolerability was excellent for both products. In terms of cosmesis, subjects across diverse curl types favored the SeS2 shampoo with significantly more agreeing that the SeS2 shampoo leaves hair soft, supple, glossy, natural appearing, and was suitable for their hair type when compared to ketoconazole (P<0.001). CONCLUSION: This micronized 0.6% SeS2 shampoo is as effective as 2% ketoconazole shampoo for treating moderate to severe scalp seborrheic dermatitis and provides superior cosmetic benefits across diverse curl types.
3. Exosome-Based Therapies in Dermatology: A Scoping Review.
This PRISMA-ScR scoping review identified 17 clinical studies of exosome-based dermatologic therapies across rejuvenation and inflammatory indications, with 76% reporting improvements in skin parameters. Rare but notable adverse events (granulomas, necrosis, allergic reactions) and low-quality designs underscore the need for rigorous trials and regulatory clarity.
Impact: Synthesizes early human evidence and safety signals for widely marketed exosome products, informing clinicians and regulators amid rapid commercialization.
Clinical Implications: Clinicians should exercise caution, counsel patients on uncertain efficacy and rare serious adverse events, and preferentially use exosome products within clinical trials or under clear regulatory oversight.
Key Findings
- Seventeen human studies (2020–2025) across rejuvenation, psoriasis, acne scars, and atopic dermatitis were identified.
- Exosomes were predominantly mesenchymal stem cell-derived and delivered via topical application, microneedling, fractional CO2 laser, or injection.
- Overall, 76% of studies reported improvements in wrinkles, pigmentation, elasticity, hydration, or scars; adverse events included granulomas, necrosis, and allergic reactions after injection.
Methodological Strengths
- PRISMA-ScR–concordant scoping methodology with multi-database and registry searches
- Focus on human studies and inclusion of grey literature to capture emerging evidence
Limitations
- Predominance of nonrandomized, single-arm, short-duration studies limits causal inference
- Potential conflicts of interest and heterogeneity preclude meta-analysis
Future Directions: Conduct standardized, randomized, controlled trials with product characterization, dosing, delivery comparators, and longer follow-up; establish safety registries and regulatory guidance.
BACKGROUND: In pre-clinical studies, exosomes activate dermal repair mechanisms, and they may show regenerative potential for skin rejuvenation, pigmentation, scarring, hair loss, and inflammatory dermatoses. However, the clinical landscape and its safety remain undefined, despite commercial availability. OBJECTIVE: To map and summarize clinical studies evaluating exosome-based dermatologic therapies, clarifying evidence, safety, and regulatory context. METHODS: A scoping review was conducted in accordance with PRISMA-ScR. Searches of MEDLINE, Embase, CENTRAL, PubMed, U.S. and E.U. trial registries, and grey literature were performed. Eligible studies involved human participants. RESULTS: Seventeen studies between 2020-2025 were identified, including cohort studies, comparative trials, and case series. Indications included skin rejuvenation, psoriasis, acne scars, and atopic dermatitis. Exosome sources were predominantly mesenchymal stem cell-derived, delivered through topical application, microneedling, fractional CO2 laser, or injection. 76% of studies recorded improvements in wrinkles, pigmentation, elasticity, hydration, or scars. Adverse events were uncommon but included granulomas, necrosis, and allergic reactions post-injection. CONCLUSIONS: Exosome-based therapies demonstrate promise for skin rejuvenation and inflammatory dermatoses. Limitations include small sample sizes and short follow-up. Interpretation is further limited by non-randomized, single-arm designs and potential conflicts of interest.